An Early Phase 1 interventional study of Tripelennamine and Diphenhydramine in Healthy, sponsored by Palm Beach Atlantic University. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Palm Beach Atlantic University · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 163 studies in Pruritus with a site in United States — 24 open to participants now, 28 under way, 8 of them phase 3. Pruritus · United States.
Among the 163 studies in Pruritus with a site in United States, this one is the 112th largest by enrollment of the 153 interventional ones that give a count, is one of 11 that started in 2025, is one of 10 in phase 1, and was the 160th registered.
491 studies on the registry are indexed under Pruritus; 94 are open to participants now.
Browse Pruritus studies →24 of the 163 studies in Pruritus with a site in United States are open now. Recruiting first, the newest first:
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Novartis Pharmaceuticals · Sites in United States, Canada, China
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Argentina, Canada and 2 more countries
Ages 18+
Paradigm Therapeutics · Sites in United States
Ages 28 days–12 yrs
Integrative Skin Science and Research · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
163 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 69 · Phase 3 48 · Phase 4 13
First in 2000; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 60 across 423 interventional studies indexed under Pruritus.
Median enrollment 70 across the 153 interventional studies, 80 across the 9 observational. Of the 126 that completed or were terminated, 80 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
108 of 163 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Palm Beach Atlantic University as lead sponsor.
Palm Beach Atlantic University has 1 study filed under Pruritus — fewer than ten, so there is no comparison to draw.
12 of the studies in Pruritus with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482787Phase 3Paradigm TherapeuticsEfficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa | 2027-05-17 |
| NCT05263206Phase 3SanofiEfficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) | 2027-06-02 |
| NCT07450716Massachusetts General HospitalAssessing the Efficacy and Safety of Photobiomodulation for the Treatment of Pruritus | 2026-12 |
| NCT07317271Johns Hopkins UniversityVR-PMR for Post-Burn Symptoms | 2026-12 |
| NCT07074977Galderma R&DProof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO) | 2026-12 |
Add all 12 to your calendar (.ics) → With an account.
Among the 163 studies in Pruritus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine whether topical tripelennamine 1% cream can relieve histamine-induced itching and whether it is more effective than diphenhydramine 1% cream in healthy adults aged 18 to 50 years.
The main questions it aims to answer are:
Participants will:
The goal of this clinical trial is to determine whether tripelennamine 1% topical cream is effective in relieving histamine-induced itching and skin reactions and whether it is more effective than diphenhydramine 1% topical cream in healthy adult volunteers aged 18 to 50 years with no history of chronic itch or conditions affecting itch perception. The study was conducted because there are limited over-the-counter topical medications that directly relieve acute itch, creating a need for more effective topical antipruritic treatments.
The main questions it aims to answer are:
Participants will:
This was a single-center, randomized, double-blind, vehicle-controlled clinical trial conducted at Palm Beach Atlantic University. Thirty-seven healthy adults were enrolled and thirty-six participants completed all efficacy assessments included in the final analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single topical application of vehicle cream base prior to histamine iontophoresis to serve as a control condition.
Drug: Vehicle Control Cream Base
Participants received a single topical application of diphenhydramine 1% cream prior to histamine iontophoresis to evaluate its effect on histamine-induced itch and skin reactions.
Drug: Diphenhydramine
Participants received a single topical application of tripelennamine 1% cream prior to histamine iontophoresis to evaluate its effect on histamine-induced itch and skin reactions.
Drug: Tripelennamine
Tripelennamine 1% topical cream applied to the skin of one arm of an individual 15 minutes before the application of iontophoretically administered histamine 2% gel.
Also known as: Pyribenzamine
Diphenhydramine 1% topical cream applied to the skin of one arm of an individual 15 minutes before the application of iontophoretically administered histamine 2% gel.
Approximately 0.2 g of vehicle cream base without antihistamine was applied topically to designated forearm test areas. The cream remained on the skin for 15 minutes before histamine iontophoresis was performed.
VAS
The effectiveness of tripelennamine 1% cream compared to diphenhydramine 1% cream in relieving histamine-induced itching was determined using a visual analogue scale for pruritus (VAS) as an endpoint. The following parameters were determined from the VAS itch score vs time curves: area under the curve, peak VAS itch score and duration of itch.
Time frame: Subjects rated their itch intensity every 60 seconds until the itch sensation had completely subsided using a visual analog scale (VAS) for 60 minutes.
Histamine Triple Response
The effectiveness of tripelennamine 1% cream compared to diphenhydramine 1% cream in relieving the histamine-induced triple response was determined via the following endpoints: * The magnitude of a wheal as a function of time. * The magnitude of a flare as a function of time.
Time frame: Research assistants rated the magnitude of the wheal and flare in 5-minute intervals for up to 20 minutes using a rating of 1-mild, 2-moderate, 3-severe.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified participant-level data supporting the published results, including demographics, VAS itch scores, itch duration, peak itch scores, wheal and flare assessments, treatment assignment, and adverse event data.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: Beginning 6 months following publication of primary results and ending 5 years after publication.
Access criteria: Available to qualified researchers upon reasonable request, review and approval of a research proposal, and execution of a Data Use Agreement.
Ran from Feb 2025 to primary completion in Sep 2025, 6 months.
Of 21 phase 1 interventional studies under Pruritus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 6 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.